Remdesivir For COVID-19 Patients To Be Sold As Remdac At Rs 2,800 Per Vial
Remdesivir has been launched under the brand name Remdac in the Indian market. Meant to treat patients suffering from severe symptoms of COVID-19, it will be priced at Rs 2,800 per 100 mg vial.
Remdac is the most economical Remdesivir brand in India, the manufacturing company Zydus Cadila was quoted as saying by Hindustan Times (HT).
The company said the drug will be made available across India through the group’s strong distribution chain reaching out to government and private hospitals treating COVID-19 patients.
“Remdac is the most affordable drug as we would like to enable patients to have access to this critical drug in the treatment of Covid-19,” Cadila Healthcare Managing Director Dr. Sharvil Patel was quoted as saying by HT.
Comments are closed.